BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

April 30, 2012 7:00 AM UTC

Alimera Sciences Inc. (NASDAQ:ALIM) jumped $0.75 (28%) to $3.44 on Tuesday after the Austrian Agency for Health and Food Safety approved Iluvien to treat chronic diabetic macular edema (DME). For the week, the stock added $0.46 (17%) to $3.23.

Alimera has rights to the injectable insert delivering sustained release fluocinolone acetonide to the retina from pSivida Corp. (NASDAQ:PSDV; ASX:PVA), which gained $0.23 (11%) to $2.40 last week and was up A$0.55 (30%) to A$2.40 in Australia...